Shidlovski Karyopharm ( NASDAQ: KPTI ) traded higher on Thursday after the company said, based on feedback from the FDA, it has redesigned its Phase 3 SENTRY Trial for its lead asset selinexor in patients with myelofibrosis, a rare form of bone marrow cancer..
Back to Health Page
